Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The US FDA can now require companies to develop a risk evaluation and mitigation strategy (REMS) for therapeutic products. Bethan Hughes investigates the recent evolution of risk-management strategies in drug development.
The pilot programme Molecular Libraries Initiative, part of the NIH Roadmap, gave academic researchers access to high-throughput screening technology and expertise. Now, as this initiative enters its next phase, a key question is how to make the most of the data generated. David Bradley investigates.
Establishing networks that tackle issues ranging from drug development bottlenecks to manufacturing standards has become a key part of Europe's strategy to improve its global competitiveness. Bethan Hughes investigates progress so far.
As a variety of novel cell- or gene-based therapies move closer to the clinic, or to market approval in a few cases, Bethan Hughes explores the rapidly evolving regulatory environment for such products.
Legislation to stimulate the development of drugs for rare diseases first came into force in the US 25 years ago. Bethan Hughes investigates the incentives and the remaining challenges for orphan drug development.
